Close Menu

NEW YORK – OpGen said Thursday that its subsidiary Curetis will have access to an additional €5 million ($5.65 million) debt financing tranche that it plans to use for research and development activities related to the COVID-19 pandemic.

The debt financing facility was originally placed in 2016 and amended in 2019, and the additional €5 million will be used to co-fund R&D programs related to COVID-19 across "several of the platforms and the entire product portfolio" of Curetis and Ares Genetics, another subsidiary of OpGen, the company said in a statement. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.